US Patent

US11730739 — Treatment of congenital adrenal hyperplasia

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2035-01-21 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using CRF1 receptor antagonists to treat congenital adrenal hyperplasia.

USPTO Abstract

CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.

Drugs covered by this patent

Crenessity (CRINECERFONT) · Neurocrine

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4049`	—	Crenessity
`U-4049`	—	Crenessity
`U-4049`	—	Crenessity
`U-4049`	—	Crenessity

Patent Metadata

Patent number: US11730739
Jurisdiction: US
Classification: Method of Use
Expires: 2035-01-21
Drug substance claim: No
Drug product claim: No
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.